Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Des 4-trans-hydroxy-glibenclamide show hypoglycemic activity?

L Balant, J Fabre, L Loutan

    Arzneimittel-Forschung
    |January 1, 1979
    PubMed
    Summary

    The main metabolite of glibenclamide, 4-transhydroxy-glibenclamide, is approximately 6.5 times less potent in reducing blood glucose levels in rats compared to glibenclamide. This study compares the hypoglycemic effects of both compounds in rodent models.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    AFSOS-SFRO-SFH-SFNEP-SFCE-GFRP guidelines on radio-induced nausea and vomiting.

    Critical reviews in oncology/hematology·2022
    Same author

    [At-risk drinking screening by general practitioners: A survey of patients in primary care].

    Revue d'epidemiologie et de sante publique·2020
    Same author

    Renal Transplantation in the Rat: Details of a Technique1.

    The Australian and New Zealand journal of surgery·2017
    Same author

    'Green Apple' Heart Failure.

    The West Indian medical journal·2015
    Same author

    Allograft response dissected.

    Immunology today·2014
    Same author

    Distribution of free amino acids, polyphenols and sugars of Ziziphus jujuba pulps harvested from plants grown in Tunisia.

    Natural product research·2014

    Area of Science:

    • Pharmacology
    • Endocrinology
    • Metabolism

    Background:

    • Glibenclamide is a widely used oral hypoglycemic agent.
    • Understanding the potency of its metabolites is crucial for drug efficacy and safety.
    • 4-transhydroxy-glibenclamide is identified as the primary metabolite in humans.

    Purpose of the Study:

    • To compare the hypoglycemic potency of glibenclamide and its main human metabolite, 4-transhydroxy-glibenclamide.
    • To evaluate the pharmacological activity of 4-transhydroxy-glibenclamide in a preclinical model.

    Main Methods:

    • Different intraperitoneal doses of glibenclamide and 4-transhydroxy-glibenclamide were administered to rats.
    • Blood glucose levels (glycemia) were measured after administration.
    • Dose-response relationships were analyzed to determine potency.

    Related Experiment Videos

    Main Results:

    • A 30% decrease in glycemia was used as a benchmark for comparison.
    • 4-transhydroxy-glibenclamide demonstrated significantly lower potency compared to glibenclamide.
    • The metabolite was found to be approximately 6.5 times less potent than the parent drug under the experimental conditions.

    Conclusions:

    • 4-transhydroxy-glibenclamide possesses reduced hypoglycemic activity compared to glibenclamide.
    • The reduced potency of the metabolite may influence the overall therapeutic effect and duration of action of glibenclamide in vivo.